BE PART OF THE FUTURE OF PARKINSON’S
TAKE PART IN PARKINSON'S CLINICAL TRIALS
Our clinical team are preparing for our upcoming clinical trials for people with Parkinson’s to further evaluate the efficacy of CUE1 for symptoms of Parkinson’s. However, with the current situation with the COVID-19 pandemic, our trials will be delayed until we are absolutely sure that it is safe for everyone to get involved in the trial.
If you would like to learn more, take a part in our future clinical research trials or participate in user testing, please do get in touch with us.
Our phase one clinical trials will be based in the UK but the information will be available for the worldwide Parkinson’s community.
Working closely with people with Parkinson’s has been a priority throughout the development of CUE1 and we plan to continue these efforts through formal clinical trials carried out in partnership with the NHS.
Make a real difference and be part of the future of non-invasive treatment for people with Parkinson’s.
OUR UPCOMING TRIALS & COMPLETED TRIALS
We are currently recruiting for two clinical trials and are interested to hear from people with Parkinson’s of all ages and at all stages.
Second Round of Clinical Trials With Production Prototype Inc. Usability
We are about to embark on our second round of trials, now with our production prototype. This time we will focus more on the usability of the device and app, and will be giving our participants a week to try it out to see the effect of CUE1 when used for a longer period of time.
User Testing of CUE1 device with Stappone Insole Sensor Technology
We partnered with Austrian company Stappone to analyse the effect of CUE1 on gait in people with Parkinson’s using their pressure-sensitive insole. MDS-UPDRS assessments were compared with objective features of gait (peak heel pressure, double support time and gait symmetry).
The findings were promising, with 100% of participants showing improvement across at least one of the objective metrics, and 60% showing improvement across two metrics (peak medial heel pressure and double support time).
Initial Proof of Concept User Testing
Our first round of trials involved 13 people with Parkinson’s across a variety of ages and stages of Parkinson’s. We had them carry out a number of movement tests including walking, moving objects and using tools with and without the device. All tests were carried out during each person’s best-medicated state.
Every single participant improved their performance with the device, at an average of 16% across all participants. More importantly, every person said they actually felt a difference in their movement, reporting for example that it was “smoother and quicker, especially walking”.